Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Disparities in initiation of combination antiretroviral treatment and in virologic suppression among patients in the HIV Outpatient Study (HOPS), 2000-2013.

Novak RM, Hart RL, Chmiel JS, Brooks JT, Buchacz K; HIV Outpatient Study (HOPS) Investigators.

J Acquir Immune Defic Syndr. 2015 Apr 13. [Epub ahead of print]

PMID:
25886926
2.

Seasonal influenza vaccination rates in the HIV outpatient study-United States, 1999-2013.

Durham MD, Buchacz K, Armon C, Patel P, Wood K, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2015 Mar 15;60(6):976-7. doi: 10.1093/cid/ciu979. Epub 2014 Dec 11. No abstract available.

PMID:
25501987
3.

Immune reconstitution inflammatory syndrome: incidence and implications for mortality.

Novak RM, Richardson JT, Buchacz K, Chmiel JS, Durham MD, Palella FJ, Wendrow A, Wood K, Young B, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

AIDS. 2012 Mar 27;26(6):721-30. doi: 10.1097/QAD.0b013e3283511e91.

PMID:
22233655
4.

Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006.

Young B, Dao CN, Buchacz K, Baker R, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2011 Apr 15;52(8):1061-8. doi: 10.1093/cid/ciq242. Epub 2011 Mar 10.

5.

Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.

Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, Wood K, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2010 Aug 15;51(4):435-47. doi: 10.1086/655144.

6.

Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007.

Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

J Viral Hepat. 2010 Dec;17(12):879-86. doi: 10.1111/j.1365-2893.2009.01249.x.

PMID:
20158604
7.

Changes in the use of HIV antiretroviral resistance testing in a large cohort of U.S. patients, 1999 to 2006.

Buchacz K, Baker RK, Young B, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):625-32. doi: 10.1097/QAI.0b013e3181bf1dd2.

PMID:
19841587
8.

Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.

Young B, Buchacz K, Moorman A, Wood KC, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2009 Aug;23(8):589-92. doi: 10.1089/apc.2008.0232.

PMID:
19591609
9.

Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.

Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

AIDS. 2008 Jul 11;22(11):1345-54. doi: 10.1097/QAD.0b013e328304b38b.

PMID:
18580614
10.

Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency.

Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, Wood KC, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):27-35.

PMID:
17971714
11.

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.

Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A; HIV Outpatient Study (HOPS) Investigators.

HIV Med. 2006 Oct;7(7):451-6.

PMID:
16925731
12.

Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.

Young B, Weidle PJ, Baker RK, Armon C, Wood KC, Moorman AC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2006 Apr;20(4):238-44.

PMID:
16623622
13.

Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort.

Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Holmberg SD, Palella FJ; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2004 Dec;18(12):721-7.

PMID:
15659883
14.

Hepatitis A and B vaccination practices for ambulatory patients infected with HIV.

Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2004 May 15;38(10):1478-84. Epub 2004 Apr 28.

15.

Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.

Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, Wood KC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2003 Feb 1;36(3):363-7. Epub 2003 Jan 14.

16.

Protease inhibitors and cardiovascular outcomes in patients with HIV-1.

Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS; HIV Outpatient Study (HOPS) investigators.

Lancet. 2002 Nov 30;360(9347):1747-8.

PMID:
12480430
17.

Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification.

Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, Moorman AC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

AIDS. 2002 Oct 18;16(15):2035-41.

PMID:
12370502
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk